Our Pricing

Your BNF Mounjaro Questions Answered

Published on: June 03, 2026

Searching for reliable mounjaro BNF UK online pharmacy information? At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance on Mounjaro (tirzepatide), including BNF classification, prescribing criteria, and dosing schedules. Mounjaro is available from £124.99 following a free online consultation with our UK prescribers.

Mounjaro BNF Classification and Licensing

In the British National Formulary (BNF), Mounjaro (tirzepatide) is classified under section 6.1.2.3 as a glucagon-like peptide-1 (GLP-1) receptor agonist, though it uniquely activates both GIP and GLP-1 receptors [1]. The Medicines and Healthcare products Regulatory Agency (MHRA) licensed Mounjaro in the UK in September 2023 for weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity.

Unlike single-pathway GLP-1 receptor agonists such as semaglutide, tirzepatide's dual mechanism produces enhanced metabolic effects. In the SURMOUNT-1 trial, participants achieved an average body weight reduction of 20.9% at the 15 mg dose over 72 weeks, compared to 2.4% with placebo [1]. This dual-agonist approach represents a significant advancement in obesity pharmacotherapy available through UK prescribers.

BNF Dosing Schedule for Mounjaro

The BNF recommends a gradual dose escalation schedule to minimise gastrointestinal side effects. Treatment begins with 2.5 mg subcutaneously once weekly for four weeks, increasing to 5 mg for the next four weeks [2]. Your UK prescriber will then assess tolerance and efficacy before considering further increases to 7.5 mg, 10 mg, 12.5 mg, or the maximum maintenance dose of 15 mg.

Each dose escalation occurs at four-week intervals, allowing your body to adapt to the medication's effects. This graduated approach significantly reduces the incidence of nausea and vomiting compared to rapid titration [2]. Our superintendent pharmacist Tarun Kumar ensures all dispensed doses align with current BNF guidance and your prescriber's specific recommendations.

Adjusting Your Mounjaro Dose

If you experience persistent gastrointestinal side effects, your prescriber may delay dose escalation by an additional four weeks. The BNF notes that remaining at a lower dose does not compromise treatment efficacy — clinical trials demonstrated meaningful weight loss across all maintenance doses [2]. Never adjust your dose without consulting your UK prescriber, as this may affect both safety and treatment outcomes.

Mounjaro Side Effects: BNF Guidance

The BNF lists gastrointestinal disturbances as the most common side effects of tirzepatide, occurring in more than 10% of patients. These include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [3]. In clinical trials, these effects were typically mild to moderate in severity and diminished over time as patients adapted to treatment.

Less common but significant side effects include acute pancreatitis, gallbladder disorders, and hypoglycaemia (particularly when used with other glucose-lowering medicines). The BNF advises prescribers to counsel patients on recognising signs of pancreatitis — persistent severe abdominal pain radiating to the back — and to discontinue treatment immediately if suspected [3]. Our UK clinical team reviews your full medical history during consultation to identify any contraindications before prescribing.

Managing Common Side Effects

To minimise nausea and gastrointestinal discomfort, the BNF recommends eating smaller, more frequent meals and avoiding high-fat foods during the initial weeks of treatment. Staying well-hydrated and administering your injection at a consistent time each week may also improve tolerance. If side effects persist beyond the first month or significantly impact your quality of life, contact your prescriber to discuss dose adjustment or alternative treatments.

BNF Prescribing Criteria for Mounjaro

According to BNF guidance, Mounjaro should only be prescribed as part of a comprehensive weight management programme that includes dietary modification and increased physical activity [4]. UK prescribers must verify that patients meet specific BMI thresholds: 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea.

The BNF recommends discontinuing treatment if patients do not achieve at least 5% body weight loss after 16 weeks at the maximum tolerated dose. This ensures appropriate use of NHS and private healthcare resources whilst prioritising patient safety [4]. At Cured Pharmacy, our UK prescribers conduct thorough clinical assessments to ensure you meet these criteria before approving your prescription.

Mounjaro Contraindications in the BNF

The BNF lists several absolute contraindications for tirzepatide, including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 [5]. Mounjaro is also contraindicated in patients with severe gastrointestinal disease, including gastroparesis and inflammatory bowel disease, as it may exacerbate these conditions.

Pregnancy and breastfeeding are additional contraindications, as animal studies demonstrated potential foetal harm and it remains unknown whether tirzepatide passes into breast milk [5]. Women of childbearing potential should use effective contraception during treatment and discontinue Mounjaro at least two months before planned conception. Our online consultation form specifically screens for these contraindications to ensure safe prescribing.

Drug Interactions to Consider

The BNF notes that tirzepatide delays gastric emptying, which may affect the absorption of oral medications. This is particularly relevant for medicines with narrow therapeutic windows, such as warfarin and levothyroxine [5]. If you take oral contraceptives, the BNF recommends using additional barrier methods for four weeks after starting Mounjaro or increasing the dose. Your UK prescriber will review all current medications during your consultation to identify potential interactions.

Comparing Mounjaro with Other BNF Weight Loss Treatments

The BNF currently lists several pharmacological options for weight management, each with distinct mechanisms and efficacy profiles. Whilst Mounjaro demonstrates superior weight loss outcomes in head-to-head trials, alternative treatments may be more suitable depending on your medical history, tolerance, and budget considerations.

Injectable GLP-1 receptor agonists like semaglutide (available as Wegovy) and liraglutide (Saxenda) work through similar pathways but with single-receptor activity. Oral options include orlistat, which reduces dietary fat absorption by approximately 30% and may be preferred by patients who wish to avoid injections [6]. Your UK prescriber will discuss these alternatives during your consultation to identify the most appropriate treatment for your circumstances.

When to Consider Alternative Treatments

If you experience persistent side effects with Mounjaro despite dose adjustment, or if the medication proves cost-prohibitive for long-term use, several BNF-listed alternatives offer effective weight management support. Semaglutide-based treatments provide robust efficacy with once-weekly dosing, whilst daily liraglutide injections allow more flexible dose titration. Oral orlistat requires no prescription for the lower 60 mg dose and may suit patients seeking non-injectable options with lower upfront costs.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity [ID6259]. NICE Technology Appraisal Guidance. https://www.nice.org.uk/guidance/indevelopment/gid-ta11235 [accessed 13 August 2026]
5. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/14443/smpc [accessed 13 August 2026]
6. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and must be prescribed following appropriate clinical evaluation.